Lymph node ratio as a risk factor for locoregional recurrence in breast cancer patients with 10 or more axillary nodes
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim S.-W.[Kim S.-W.] | - |
dc.contributor.author | Choi D.H.[Choi D.H.] | - |
dc.contributor.author | Huh S.J.[Huh S.J.] | - |
dc.contributor.author | Park W.[Park W.] | - |
dc.contributor.author | Nam S.J.[Nam S.J.] | - |
dc.contributor.author | Kim S.W.[Kim S.W.] | - |
dc.contributor.author | Lee J.E.[Lee J.E.] | - |
dc.contributor.author | Im Y.-H.[Im Y.-H.] | - |
dc.contributor.author | Ahn J.S.[Ahn J.S.] | - |
dc.contributor.author | Park Y.H.[Park Y.H.] | - |
dc.date.accessioned | 2021-08-01T02:25:47Z | - |
dc.date.available | 2021-08-01T02:25:47Z | - |
dc.date.created | 2021-06-22 | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 1738-6756 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/38609 | - |
dc.description.abstract | Purpose: We analyzed the association of lymph node ratio (LNR) wth locoregional control (LRC) in breast cancer patients with ≥10 involved axillary lymph nodes who underwent multimodality treatment. Methods: We retrospectively analyzed 234 breast cancer patients with ≥10 involved axillary lymph nodes between 2000 and 2011. All patients received adjuvant chemotherapy and radiotherapy (RT) after radical surgery. The cutoff value of LNR was obtained using receiver operating characteristic curve analysis. The majority of patients (87.2%) received chemotherapeutic regimen including taxane. RT consisted of tangential fields to the chest wall or intact breast, delivered at a median dose of 50 Gy, and a single anterior port to the supraclavicular lymph node area, delivered at a median dose of 50 Gy. For patients who underwent breast-conserving surgery, an electron boost with a total dose of 9 to15 Gy was delivered to the tumor bed. Results: Within a median follow-up period of 73.5 months (range, 11–183 months), locoregional recurrence (LRR) occurred in 30 patients (12.8%) and the 5-year LRC rate was 88.8%. After multivariate analysis, LNR ≥0.7 was the only independent factor significantly associated with LRC (hazard ratio, 2.06; 95% confidence interval, 0.99–4.29; p=0.05). Conclusion: An aggressive multimodal treatment approach showed favorable locoregional outcome in patients with ≥10 involved axillary lymph nodes. However, patients with a high LNR ≥0.7 still had an increased risk for LRR, even in the setting of current local treatments. © 2016 Korean Breast Cancer Society. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Korean Breast Cancer Society | - |
dc.subject | anthracycline | - |
dc.subject | aromatase inhibitor | - |
dc.subject | cyclophosphamide | - |
dc.subject | epidermal growth factor receptor 2 | - |
dc.subject | fluorouracil | - |
dc.subject | hormone receptor | - |
dc.subject | methotrexate | - |
dc.subject | selective estrogen receptor modulator | - |
dc.subject | taxane derivative | - |
dc.subject | trastuzumab | - |
dc.subject | adjuvant chemotherapy | - |
dc.subject | adult | - |
dc.subject | apocrine carcinoma | - |
dc.subject | Article | - |
dc.subject | axillary lymph node | - |
dc.subject | breast cancer | - |
dc.subject | cancer prognosis | - |
dc.subject | carcinoma | - |
dc.subject | computer assisted tomography | - |
dc.subject | female | - |
dc.subject | fluoroscopy | - |
dc.subject | follow up | - |
dc.subject | histology | - |
dc.subject | human | - |
dc.subject | invasive micropapillary carcinoma | - |
dc.subject | invasive tubulolobular carcinoma | - |
dc.subject | locoregional recurrence risk | - |
dc.subject | lymph node ratio | - |
dc.subject | lymph vessel metastasis | - |
dc.subject | major clinical study | - |
dc.subject | menstruation | - |
dc.subject | metaplastic carcinoma | - |
dc.subject | middle aged | - |
dc.subject | mixed cell carcinoma | - |
dc.subject | multimodality cancer therapy | - |
dc.subject | partial mastectomy | - |
dc.subject | recurrence risk | - |
dc.title | Lymph node ratio as a risk factor for locoregional recurrence in breast cancer patients with 10 or more axillary nodes | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi D.H.[Choi D.H.] | - |
dc.contributor.affiliatedAuthor | Huh S.J.[Huh S.J.] | - |
dc.contributor.affiliatedAuthor | Park W.[Park W.] | - |
dc.contributor.affiliatedAuthor | Nam S.J.[Nam S.J.] | - |
dc.contributor.affiliatedAuthor | Lee J.E.[Lee J.E.] | - |
dc.contributor.affiliatedAuthor | Im Y.-H.[Im Y.-H.] | - |
dc.contributor.affiliatedAuthor | Ahn J.S.[Ahn J.S.] | - |
dc.contributor.affiliatedAuthor | Park Y.H.[Park Y.H.] | - |
dc.identifier.doi | 10.4048/jbc.2016.19.2.169 | - |
dc.identifier.scopusid | 2-s2.0-84977522187 | - |
dc.identifier.wosid | 000378973000009 | - |
dc.identifier.bibliographicCitation | Journal of Breast Cancer, v.19, no.2, pp.169 - 175 | - |
dc.relation.isPartOf | Journal of Breast Cancer | - |
dc.citation.title | Journal of Breast Cancer | - |
dc.citation.volume | 19 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 169 | - |
dc.citation.endPage | 175 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordPlus | anthracycline | - |
dc.subject.keywordPlus | aromatase inhibitor | - |
dc.subject.keywordPlus | cyclophosphamide | - |
dc.subject.keywordPlus | epidermal growth factor receptor 2 | - |
dc.subject.keywordPlus | fluorouracil | - |
dc.subject.keywordPlus | hormone receptor | - |
dc.subject.keywordPlus | methotrexate | - |
dc.subject.keywordPlus | selective estrogen receptor modulator | - |
dc.subject.keywordPlus | taxane derivative | - |
dc.subject.keywordPlus | trastuzumab | - |
dc.subject.keywordPlus | adjuvant chemotherapy | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | apocrine carcinoma | - |
dc.subject.keywordPlus | Article | - |
dc.subject.keywordPlus | axillary lymph node | - |
dc.subject.keywordPlus | breast cancer | - |
dc.subject.keywordPlus | cancer prognosis | - |
dc.subject.keywordPlus | carcinoma | - |
dc.subject.keywordPlus | computer assisted tomography | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | fluoroscopy | - |
dc.subject.keywordPlus | follow up | - |
dc.subject.keywordPlus | histology | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | invasive micropapillary carcinoma | - |
dc.subject.keywordPlus | invasive tubulolobular carcinoma | - |
dc.subject.keywordPlus | locoregional recurrence risk | - |
dc.subject.keywordPlus | lymph node ratio | - |
dc.subject.keywordPlus | lymph vessel metastasis | - |
dc.subject.keywordPlus | major clinical study | - |
dc.subject.keywordPlus | menstruation | - |
dc.subject.keywordPlus | metaplastic carcinoma | - |
dc.subject.keywordPlus | middle aged | - |
dc.subject.keywordPlus | mixed cell carcinoma | - |
dc.subject.keywordPlus | multimodality cancer therapy | - |
dc.subject.keywordPlus | partial mastectomy | - |
dc.subject.keywordPlus | recurrence risk | - |
dc.subject.keywordAuthor | Breast neoplasms | - |
dc.subject.keywordAuthor | Local recurrence | - |
dc.subject.keywordAuthor | Lymph node ratio | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu
COPYRIGHT © 2021 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.